Measles is one of the most prevalent and serious infectious disease among children in the third world countries contributing to a high degree of morbidity and mortality unless they are either protected by high maternal antibody titer or by vaccination. Some work is still required regarding the optimum age of measles vaccination in developing countries. The present study was undertaken to find out the age where maternal antibodies declined and indicate the appropriate age for vaccination. A total of 606 blood samples were collected. 449 including 39 cord samples were collected from unvaccinated children between 0-36 months. 157 samples were analyzed for antibody response to live attenuated measles virus vaccine in 10-36 months. Haemagglutination Inhibition test (HI) was used to obtain stable titers. The percentage of maternal antibodies varied in each group. The highest antibodies 100% were observed in cord blood and 0-1 months of age group while lowest 17.39% in nine months. A large increase in active immune response after vaccination was observed. The geometric mean titer (GMT) being significantly different before and after vaccination. At 13-24 months GMT was 5.038% before and 77.25% after vaccination. At 25-36 months GMT was 5.038% before and 87.2% after vaccination. It is concluded from this study that optimal age of measles vaccination in children is nine months.
INTRODUCTION
A vaccine is so far the best antidote available to immunize the world against measles also called child-killer disease (17) . Intensive vaccination programs all over the world have reduced the death toll by measles to 71% between 2000-2011, with reduced mortality i.e. 1 out of 100. Despite this success, the virus continues to cause chaos in the form of (5) . https://doi.org/10.24087/IAM.2017. 1.7.198 outbreaks in different countries especially in developing world. Almost one million children die of measles annually. Blindness, diarrhea, and malnutrition are caused in many children who survive measles (2, 17) . WHO has recommended that vaccine should be administered at the age of nine months in developing countries as at this age most of the infants have lost maternal antibodies (4, 10) . In Pakistan, a live attenuated virus vaccine is given to infants at 9 and 15 months of age but no data available regarding maternal antibodies prevalence in infants which would give protection until the age of vaccination. 4386 cases in the year 2011, 8046 in 2012 and 8749 cases of measles were reported in 2013 from Pakistan (18) . The rate of decline of MMA was reviewed during infancy (16) . It was also described that three factors need consideration to determine the earliest possible age for vaccination against measles virus. Time of waning of antibodies of maternal origin, the rate of incidence of measles infection in early months of life and efficiency of vaccination before the age of 12 months (17) . The occurrence of measles among infants younger than nine months of age often raises questions of whether the minimum age of vaccination should be between 6-9 months. In view of this controversy need for defining the minimum age for measles vaccination arises. Therefore this study was undertaken to determine the age up to which protection level of maternal antibodies against measles virus is maintained in our infant population of Rawalpindi and Islamabad.
METHODS
606 blood samples were collected randomly from vaccinated and unvaccinated children having age 0-36 months. 449 blood samples including 39 cord samples collected from unvaccinated children were surveyed for the prevalence of maternal antibodies. 157 samples were collected from 10-36 months old, vaccinated children from EPI centers of Rawalpindi and Islamabad. However, cord samples were collected from newly born children in Federal Government Services Hospital Islamabad. Serum samples were used for serological tests to confirm and quantify the maternal antibodies against measles virus. Collected blood specimens were clot at 4⁰C; serum was separated by centrifugation at 2500 rpm for 5-10 minutes. Each sample was labeled and kept separately in sterile ampoules at -20⁰C.
HI titer of each serum sample was determined by the technique described by (12) . Blood was collected from Rhesus monkey and was placed in Alsever's solution to maintain the ratio of one volume of blood to four volumes of anticoagulant solution. RBCs were obtained from preselected monkeys which were seronegative against measles virus, and their RBCs had shown strong positive HA reaction with measles antigen. The stored cell suspension was centrifuged at 2500 rpm for 10 minutes. The supernatant was discarded, and RBCs were resuspended in 10 ml physiological saline. The process repeated till the clear solution is obtained. The washed RBCs were preserved in the equal volume of Alsever's solution at 4⁰C. Stored sera were inactivated at 56⁰C to eliminate nonspecific inhibitors. For removal of natural agglutinin, sera were adsorbed with an equal volume of 50% monkey RBCs in physiological saline and RBC were removed by centrifugation at 200 rpm for 15 minutes.
Reagents:
The antigen used in this study was obtained from National Institute of Biological Standard & Control, London and stored in different aliquots at negative temperature & 0⁰C. The working reference antisera were prepared in the laboratory by pooling the triple positive human serum, and their titer was standardized by HI test. Negative control serum prepared from the pooled susceptible samples. Before each series of reaction, the antigen was titrated to ensure that working solution contains 4 HAU. The highest dilution of antigen giving complete HA is the end point and contains 1 HAU. The final dilution of antigen was prepared with the ratio to that of 4 HAU in physiological saline. To determine HI titer all treated (inactivated and adsorbed) sera were prepared to make serial dilutions. Titer tech/greener microtiter plate was used for dilutions. All wells were filled with 50µl of sterile physiological saline. 50 µl of serum dilution was transferred from the first row to the second row. This procedure is repeated till 8th row, thus diluting each to 1:4 up to 1:512. Antigen was added and mixed properly. Plates were kept for one hour at room temperature after incubation 50µl of 0.5% washed RBC suspension was added. Plates were shaken and kept at 37⁰C for 30-120 minutes. Control wells were included as a check on the specificity and reproducibility of the test.
Controls:
1. Serum without antigen at the lowest dilution. 2. 50µl of 0.5% RBC with sterile physiological saline. 3. Positive & negative controls (sera of known titers) also included.
Evaluation of results:
Plates were read on the mirror for hemagglutination inhibition. When control wells showed compact buttons, the serum HI titer was the highest dilution of serum, showing complete inhibition of agglutination. The HI titer was expressed as reciprocal of the dilution of serum in the well which was taken as the end point.
Results of the HI titers of all the sera thus obtained were recorded, and geometric mean titers (G.M.T) were calculated.
RESULTS
All treated samples were screened at 1:4 dilutions for the presence of HI titer. Sera samples with no antibody activity at 1:4 were assumed as seronegative, samples showing antibody activity at 1:4 were considered as seropositive. These samples were further titrated from1:4 to 1:512 dilutions.
Cord blood samples and 0-1 months of age group blood samples were 100 % positive with G. 
DISCUSSION
Three factors are considered in determining the earliest possible age for vaccination against measles (8) :
1. The time of waning of antibodies of maternal origin. 2. The rate of incidence of measles infection in early months of life. 3. The efficiency of vaccination before the age of 12 months.
Time of waning was given priority in this study as no such study has commenced in Pakistan before. In present study 449 blood samples including 39 cord samples were collected from unvaccinated children 0-36 months for comparing the prevalence of maternal antibodies against measles. However, 157 random samples were collected from vaccinated children 10-36 months to check seroconversion rate of Measles Live Attenuated Virus Vaccine. In our study results indicates that age played the significant influence on the comparison of prevalence of maternal antibodies against measles virus (Table 1  & 2) . Children between 0-3 months showed high measles antibody titer. It declined at the age of 4-6 months and was lowest at 7-9 months. It was shown that mother's antibodies provide protection against measles to infants' only up to 2.61 months of age (13) . As immunity wanes gradually between 3-9 months about 90% of infants were found susceptible to measles infection. It was also found that at the age of 09 months almost no protection at all in German children (11) . One of the Scientist described that maternal antibodies were 100% at the age of one month, but at 7-9 months several children didn't have detectable titers (15) . Maternal antibodies protect all the infants up to 03 months (1) . It was also found that at the age of 06 months only 10% of children are protected by maternal antibodies in a French population (7) . In our study declining patterns of maternal antibodies in different age group was 88.4% at 0-3 months, 64.21% at 4-6 months with further decline 23.7% at 7-9 months (Table 3) , i.e., the lowest HI titer was observed in this group. Antibody level was found to decrease from 88.42% at the age of 0-3 months to 23.47% at the age of 7-9 months. It then again started rising by the age of 36 months, and 70% of children acquired immunity. Maternal antibodies were present in all 39 cord blood samples, (Table 2 & 3) . The antibody level detected above 1:512 titer in 12.8% with high G.M.T 121.35. It is satisfactory to note that Pakistani mothers are sufficiently immune to pass maternal antibodies to children and henceforth an incidence of 100 % seropositivity was observed in 0-1 month children. The result of post vaccinated random samples up to 10-36 months revealed that significant difference in seropositive percentage amongst vaccinated and unvaccinated groups exists (Table 7, 8 ). In our study, the passive immunity acquired through placental transfer is observed to protect 88.4 % infants up to three months. As immunity wanes gradually between 3-9 months of age and about 83 % infants were found susceptible to the infection after nine months of age. Therefore more infants are at the risk of acquiring measles after nine months of age and need protection. Thus nine months may be defined as the minimum age for routine vaccination. These age limits have also been recommended (3, 11, 17) . Our result of post immunization after nine months supported that seroconversion rate was found 90.67%. The nine month age for immunization of measles was also supported by (13) . Though in our study the numbers of susceptible children start increasing after three months of age and reach a peak by nine months. Yet 63% infants had shown adequate passive immunity at four months while 17.39% had shown immunity at nine months of age. If the minimum age of vaccination is reduced to protect the children below nine months, maternal antibodies may interfere with the response to measles vaccine as reported by several investigators (5, 6) .
CONCLUSION
Our study has shown that 09 months age for vaccination against measles is more appropriate as maternal antibodies are unable to provide immunity against measles anymore.
